Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 15;13:10475–10487. doi: 10.2147/OTT.S253758

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Sun et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Targeting CDC20 inhibits tumorigenesis of DLBCL in vivo. (A) OCI-Ly10 cells (5×10⁶ cells per mouse) were subcutaneously injected into the posterior ﬂank of NOD/SCID mice. After 9 days, the mice were randomly divided into two groups and treated with PBS or Apcin. Photographed tumors of these two groups on day 27 are shown. (B and C) The primary tumor volume and weight are also illustrated. (D) Western blotting and IHC (× 200; scale bar, 50 μm) were performed to estimate the protein expressions of MDM2, wtp53, and CDC20 in two groups. *P < 0.05; **P < 0.01.

Abbreviations: DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry.